We see strong sales growth in FY 2024E (18% organic) mainly due to BD revenue recovering from depressed levels in 2023. This, coupled with enhanced cost management, leads us to project EBITDA turns positive, which is favourable for the investment case. Investors are likely searching for new license deals, but news flow regarding this has been muted recently. The market is also awaiting new financial targets from the company (currently under review).
LÄS MER
